Search

Trevena announced an amendment to its March 2022 ex-US royalty-based financing with R-Bridge Healthcare Fund. Pursuant to the Amendment, Trevena will receive a $2 million payment from R-Bridge to Trevena, [...]

'Despite OLINVYK's differentiated profile, the hospital environment continues to be challenging. Given performance to date, we are reducing commercial support and reviewing alternatives for OLINVYK to preserve capital,' said Carrie [...]

Trevena announced completion of initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study. The VOLITION study, a real-world, open-label, multi-site study, assessed the potential impact of OLINVYK [...]

Trevena announced receipt of a $15M tranche under its non-dilutive ex-US royalty-based financing. This tranche of funding was triggered by the first commercial sale of OLINVYK in China by Jiangsu [...]

Trevena announced receipt of a $15 million tranche under its non-dilutive ex-US royalty-based financing. This tranche of funding was triggered by the first commercial sale of OLINVYK in China by [...]

Trevena announced new topline OLINVYK data from the ARTEMIS study. The ARTEMIS study was an electronic medical records based assessment focused on clinical and health resource utilization outcomes at Cleveland [...]

The Company also reaffirmed expected timing of its many near-term milestones: TRV045 Target Engagement Study. Topline data from the clinical proof-of-concept study, expected 3Q 2023; TRV045 Transcranial Magnetic Stimulation Study. [...]

Reports Q1 revenue $6,000, consensus $230,000. 'This is an important year for Trevena as we expect topline data from two TRV045 proof-of-concept studies, one to support potential use in epilepsy [...]

Trevena announced that its partner in China, Jiangsu Nhwa, received formal approval from the National Medical Products Administration for OLINVYK. It has been approved for use in adults for the [...]

'We are excited to report initial topline data from the OLINVYK real-world outcomes studies, VOLITION and ARTEMIS. The GI and cognitive results build upon the extensive data set for OLINVYK, [...]

Trevena announced that an abstract entitled, 'A Randomized Double-blind Trial Comparing Oliceridine And Morphine On Ventilation In An Elderly Population' has been accepted for podium presentation in the 'Best of [...]

Reports Q2 revenue $0, consensus $350,000. 'We recognize the macro headwinds our hospital customers are facing and have made disciplined choices around our business to efficiently commercialize OLINVYK with our [...]

Trevena reported positive topline results from its post-approval study designed to assess the impact on cognitive function in subjects treated with OLINVYK compared to IV morphine. 'We are pleased to [...]

General business updates: Executed a contract in July with a leading hospital group purchasing organization, which will allow for broad OLINVYK access for member hospitals. The hospital GPO has coverage [...]

Trevena announced a publication in Expert Review of Neurotherapeutics titled 'A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain' by Eugene [...]

'In the first quarter, we began to see hospitals opening up post the pandemic as evidenced by accelerated field execution of the OLINVYK strategy and an increase in educational programs [...]

Trevena announced results from its double blinded, crossover study evaluating OLINVYK injection for the management of acute pain, in elderly/overweight. This study builds on the collaborative work with Dr. Albert [...]

Trevena announced receipt of the first $15M tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund. The R-Bridge Financing calls for an initial $15M tranche within [...]

Trevena announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund. In connection with the R- Bridge Financing, Trevena will receive an upfront amount [...]

Reports Q4 revenue ($1,000), consensus $460k. '2021 was an important year for Trevena as we launched OLINVYK in the hospital setting. Our sales and marketing team, led by our new [...]

Trevena announced two presentations at ANESTHESIOLOGY 2021, the national conference for the American Society of Anesthesiologists, or ASA. Both posters highlighted safety data from the OLINVYK injection program. The meeting [...]

Trevena announced the acceptance of two abstracts at ANESTHESIOLOGY 2021. Both abstracts highlight safety data from the OLINVYK injection program. The meeting is sponsored by the American Society of Anesthesiologists [...]

Trevena announced Wake Forest Baptist Health Medical Center will join the VOLITION study which examines the impact of OLINVYK injection on respiratory, gastrointestinal, and cognitive function outcomes in the postoperative [...]

Trevena announced the publication of an exploratory analysis evaluating the safety of OLINVYK injection and IV morphine, using data from the OLINVYK Phase 3 program. The findings suggest that under [...]

Trevena announced the publication of the health economic model for OLINVYK injection in Journal of Comparative Effectiveness Research. The model estimates the budget impact of OLINVYK compared to IV morphine [...]